Miguel Tarón - Concepedia

Concepedia

Author

Miguel Tarón

Hospital Universitari Germans Trias i Pujol

Also Known As

M. Taron, M. Tarón, Miguel Taron, Miguel Tarón

65

Publications

1.3K

Citations

12

H-Index

15

Concepts

All Affiliations

Hospital Universitari Germans Trias i Pujol Institut Català d'Oncologia Instituto de Biomedicina de Sevilla Hospital Universitario Virgen del Rocío Hospital Universitario Miguel Servet

MT

About

Miguel Tarón is an author at Hospital Universitari Germans Trias i Pujol specializing in medicine, pathology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	7	7	389
2	Pathology	7	7	389
3	Cancer Genetics	4	4	109
4	Surgical Oncology	3	3	235
5	Cancer Therapeutics	3	3	99

Miguel Tarón

×

14

Publications

1.3K

Citations

12

H-Index

	Year	Citations
Activating Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor Are Associated with Improved Survival in Gefitinib-Treated Chemorefractory Lung Adenocarcinomas Miguel Tarón, Yukito Ichinose, Rafael Rosell, Clinical Cancer Research	2005	336
Brain metastases from lung cancer responding to erlotinib: the importance of<i>EGFR</i>mutation R. Porta, J.M. Sánchez-Torres, Luis Paz‐Ares, European Respiratory Journal	2010	316
Endobronchial ultrasound-guided transbronchial needle aspiration for identifying EGFR mutations Ignasi García-Olivé, Eduard Monsó, Felipe Andreo, European Respiratory Journal	2009	132
Pazopanib for treatment of advanced malignant and dedifferentiated solitary fibrous tumour: a multicentre, single-arm, phase 2 trial Javier Martín‐Broto, Silvia Stacchiotti, Antonio López–Pousa, The Lancet Oncology Surgical OncologyMedicineMetronomic TherapyPathologyAdvanced Malignant	2018	131
Predictive impact of DNA repair functionality on clinical outcome of advanced sarcoma patients treated with trabectedin: A retrospective multicentric study Patrick Schöffski, Miguel Tarón, José Jimeno, European Journal of Cancer Advanced Sarcoma PatientsSurgical OncologyRetrospective Multicentric StudyMedicinePathology	2011	92
Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS) Javier Martín‐Broto, Andrés Redondo, Claudia Valverde, Annals of Oncology Spanish GroupOsteosarcoma PatientsOncologyStandard ChemotherapyMetronomic Therapy	2017	57
Assessment of Nucleotide Excision Repair XPD Polymorphisms in the Peripheral Blood of Gemcitabine/Cisplatin–Treated Advanced Non–Small-Cell Lung Cancer Patients Carlos Camps, Carmen Sarries, Bárbara Roig, Clinical Lung Cancer MedicinePathologyPeripheral BloodBronchial NeoplasmMolecular Diagnostics	2003	54
Nilotinib as Coadjuvant Treatment with Doxorubicin in Patients with Sarcomas: A Phase I Trial of the Spanish Group for Research on Sarcoma Regina Alemany, David S. Moura, Andrés Redondo, Clinical Cancer Research	2018	40
Trabectedin in patients with advanced non-small-cell lung cancer (NSCLC) with XPG and/or ERCC1 overexpression and BRCA1 underexpression and pretreated with platinum Bartomeu Massutí, Manuel Cobo, Carlos Camps, Lung Cancer Ercc1 OverexpressionMedicinePathologyCancer TreatmentCancer Genetics	2011	30
Combined analysis of genetic polymorphisms in thymidylate synthase, uridine diphosphate glucoronosyltransferase and X-ray cross complementing factor 1 genes as a prognostic factor in advanced colorectal cancer patients treated with 5-fluorouracil plus oxaliplatin or irinotecan Eva Martinez‐Balibrea, Jose Manzano, Anna Martínez‐Cardús, Oncology Reports	2007	27

Page 1